News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
520,062 Results
Type
Article (13363)
Company Profile (142)
Press Release (508672)
Multimedia
Podcasts (96)
Webinars (10)
Section
Business (176216)
Career Advice (435)
Deals (27138)
Drug Delivery (76)
Drug Development (58574)
Employer Resources (20)
FDA (11002)
Job Trends (9508)
News (255758)
Policy (21897)
Tag
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (2)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (723)
Accelerated approval (38)
ADA (35)
Adcomms (9)
Allergies (119)
Alliances (35306)
ALS (150)
Alzheimer's disease (1269)
Antibody-drug conjugate (ADC) (356)
Approvals (11626)
Artificial intelligence (406)
ASCO (191)
Autoimmune disease (240)
Automation (33)
Bankruptcy (278)
Belgium (1)
Best Places to Work (7695)
BIO (42)
Biologics (9)
BIOSECURE Act (3)
Biosimilars (155)
BioSpace Insights (28)
Biotechnology (91)
Bladder cancer (158)
Brain cancer (52)
Breast cancer (570)
Cancer (4292)
Cardiovascular disease (335)
Career advice (355)
Career pathing (6)
CAR-T (209)
CDC (9)
CDMO (52)
Celiac Disease (1)
Cell therapy (564)
Cervical cancer (36)
Clinical research (52471)
Collaboration (1466)
Commercialization (5)
Company closure (1)
Compensation (1532)
Complete response letters (50)
COVID-19 (1221)
CRISPR (71)
C-suite (898)
Cystic fibrosis (99)
Data (6318)
Denatured (5)
Depression (130)
Dermatology (83)
Diabetes (497)
Diagnostics (4465)
Digital health (43)
Diversity (2)
Diversity, equity & inclusion (7)
Drug discovery (209)
Drug pricing (111)
Drug shortages (31)
Duchenne muscular dystrophy (211)
Earnings (77036)
Editorial (27)
Employer branding (3)
Employer resources (23)
Events (92422)
Executive appointments (792)
FDA (13985)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (19)
Frontotemporal dementia (27)
Funding (1130)
Gene editing (154)
Generative AI (22)
Gene therapy (416)
GLP-1 (890)
Government (2539)
Grass and pollen (3)
Guidances (307)
Healthcare (10663)
Hematology (107)
HIV (67)
Huntington's disease (35)
IgA nephropathy (79)
Immunology and inflammation (176)
Immuno-oncology (80)
Indications (176)
Infectious disease (1459)
Inflammatory bowel disease (147)
Inflation Reduction Act (8)
Influenza (98)
Intellectual property (270)
Interviews (68)
IPO (12950)
IRA (18)
Job creations (2190)
Job search strategy (327)
JPM (27)
Kidney cancer (22)
Labor market (19)
Layoffs (135)
Leadership (8)
Legal (5663)
Licensing (17)
Liver cancer (54)
Longevity (22)
Lung cancer (608)
Lymphoma (319)
Machine learning (35)
Management (5)
Manufacturing (757)
Marketing (8)
MASH (144)
Medical affairs (2)
Medical device (9415)
Medtech (9580)
Mergers & acquisitions (15286)
Metabolic disorders (1361)
mRNA (114)
Multiple sclerosis (123)
NASH (14)
Neurodegenerative disease (332)
Neuropsychiatric disorders (71)
Neuroscience (2358)
Neurotech (1)
NextGen: Class of 2026 (3434)
Non-profit (1319)
Now hiring (43)
Obesity (696)
Opinion (76)
Ovarian cancer (186)
Pain (205)
Pancreatic cancer (231)
Parkinson's disease (240)
Partnered (13)
Patents (528)
Patient recruitment (581)
Patient selection (1)
Peanut (43)
People (43818)
Peptides (2)
Pharmaceutical (32)
Pharmacy benefit managers (12)
Phase 1 (16541)
Phase 2 (23105)
Phase 3 (16676)
Pipeline (8356)
Policy (121)
Postmarket research (1801)
Preclinical (6933)
Press Release (41)
Prostate cancer (221)
Psychedelics (43)
Radiopharmaceuticals (257)
Rare diseases (717)
Real estate (3299)
Recruiting (11)
Regenerative medicine (1)
Regulatory (17621)
Reports (34)
Research institute (803)
Resumes & cover letters (63)
Rett syndrome (44)
RNA editing (11)
RSV (60)
Schizophrenia (136)
Series A (193)
Series B (153)
Service/supplier (6)
Sickle cell disease (72)
Special edition (16)
Spinal muscular atrophy (101)
Sponsored (11)
Startups (2227)
Stomach cancer (8)
Supply chain (86)
Tariffs (65)
The Weekly (95)
Vaccines (585)
Venture capital (53)
Weight loss (502)
Women's health (95)
Worklife (2)
Date
Today (90)
Last 7 days (435)
Last 30 days (1569)
Last 365 days (21007)
2026 (14884)
2025 (20949)
2024 (24963)
2023 (28295)
2022 (37635)
2021 (40673)
2020 (36965)
2019 (26346)
2018 (19818)
2017 (20456)
2016 (19661)
2015 (25885)
2014 (22802)
2013 (18996)
2012 (20989)
2011 (21260)
2010 (21088)
Location
Africa (312)
Alabama (81)
Alaska (3)
Arizona (315)
Arkansas (11)
Asia (20366)
Australia (2688)
California (12548)
Canada (3812)
China (667)
Colorado (523)
Connecticut (440)
Delaware (226)
Europe (31908)
Florida (1880)
Georgia (397)
Hawaii (3)
Idaho (49)
Illinois (773)
India (70)
Indiana (594)
Iowa (23)
Japan (456)
Kansas (108)
Kentucky (31)
Louisiana (29)
Maine (28)
Maryland (1298)
Massachusetts (8385)
Michigan (315)
Minnesota (587)
Mississippi (4)
Missouri (101)
Montana (21)
Nebraska (14)
Nevada (127)
New Hampshire (69)
New Jersey (2973)
New Mexico (13)
New York (2976)
North Carolina (1388)
North Dakota (4)
Northern California (6310)
Ohio (321)
Oklahoma (14)
Oregon (20)
Pennsylvania (2390)
Puerto Rico (25)
Rhode Island (31)
South America (498)
South Carolina (79)
South Dakota (1)
Southern California (5188)
Tennessee (130)
Texas (2067)
United States (41562)
Utah (373)
Vermont (2)
Virginia (167)
Washington D.C. (50)
Washington State (977)
West Virginia (1)
Wisconsin (77)
Wyoming (1)
520,062 Results for "eli lilly canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
Teams at facilities being developed by Eli Lilly, Regeneron and other companies will receive early technical guidance and additional perks from the FDA.
July 1, 2026
·
2 min read
·
Nick Paul Taylor
Weight loss
Lilly takes oral obesity race abroad with UK launch of Foundayo
Eli Lilly’s best play for Foundayo is to bring it overseas, a more price-sensitive market where the pharma can more readily outcompete Novo Nordisk “given the high margins of a small-molecule therapy,” Truist analyst Srikripa Devarakonda told
BioSpace
.
August 25, 2026
·
1 min read
·
Tristan Manalac
FDA
Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjaro
With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes.
August 28, 2026
·
2 min read
·
Heather McKenzie
Earnings
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the end of July.
August 5, 2026
·
2 min read
·
Annalee Armstrong
Approvals
Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry
The FDA approved Eli Lilly’s orforglipron—to be known as Foundayo—on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.
April 1, 2026
·
3 min read
·
Heather McKenzie
Mergers & acquisitions
Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
With the acquisition of Merida Biosciences, Eli Lilly is gaining a precision degradation platform for therapies that selectively target and destroy pathologic antibodies for allergic and autoimmune diseases.
August 31, 2026
·
2 min read
·
Tristan Manalac
Psychedelics
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
Eli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unlikely to trigger a broad wave of Big Pharma deals.
July 24, 2026
·
3 min read
·
Gabrielle Masson
Psychedelics
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst cautioned, however, that the transaction should not be seen as “supporting a uniform re-rating of every psychedelic developer.”
July 20, 2026
·
3 min read
·
Heather McKenzie
Press Releases
ELI LILLY CANADA WELCOMES QUÉBEC PUBLIC REIMBURSEMENT OF VERZENIO® (ABEMACICLIB) FOR MBC FOLLOWING SUCCESSFUL PCPA NEGOTIATION
June 10, 2026
·
6 min read
Press Releases
Veeva Vault CRM Selected by Eli Lilly and Company
August 11, 2026
·
2 min read
1 of 52,007
Next
